← All stories← All stories
Federal Policy·June 5, 2026
FDA Launches Safety Review of Abortion Drug Mifepristone
The Food and Drug Administration has initiated a safety review of mifepristone, the abortion medication, according to an administration official. The retrospective analysis could lead to restrictions on the drug's use and distribution channels. Anti-abortion groups view this as a significant development that may result in tighter federal controls over medication abortion access. The timing and scope of the review have not been disclosed.
Why it matters for managed care
If FDA restricts mifepristone distribution or availability, Medicaid managed care plans may face changes to pharmacy networks, prior authorization protocols, and access to medication abortion services covered under state Medicaid programs.
Maternal · Pharmacy · Managed Care
You might also like